(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014782 A2

(51) International Patent Classification[7]: C12N

(21) International Application Number:
PCT/US2004/018848

(22) International Filing Date: 14 June 2004 (14.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

03013296.3	13 June 2003 (13.06.2003)	EP
60/479,354	18 June 2003 (18.06.2003)	US
04002374.9	3 February 2004 (03.02.2004)	EP

(71) Applicant *(for all designated States except US)*: **ALNYLAM PHARMACEUTICALS** [US/US]; 300 Third Street, Cambridge, MA 02142 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **WOPPMANN, Claudia** [DE/DE]; Lerchenweg 9, 95494 Gesees (DE). **VORNLOCHER, Hans-Peter** [DE/DE]; Lise-Meitner-Platz 4, 95448 Bayreuth (DE). **HADWIGER, Philipp** [AT/DE]; Schlesierstr. 6, 96264 Altenkunstadt (DE). **JOHN, Matthias** [DE/DE]; Kapellenstr. 12, 96103 Hallstadt (DE).

(74) Agents: **GORDON, Dana, M.** et al.; Patent Group, Foley Hoag LLP, Seaport World Trade Center West,, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/014782 A2

(54) Title: DOUBLE-STRANDED RIBONUCLEIC ACID WITH INCREASED EFFECTIVENESS IN AN ORGANISM

(57) Abstract: The present invention relates to a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least end of the dsRNA comprises a nucleotide overhang of 1 to 4 unpaired nucleotides in length; wherein the unpaired nucleotide adjacent to the terminal nucleotide pair comprises a purine base; and wherein the terminal nucleotide pair on both ends of the dsRNA is a G-C pair, or at least two of the last four consecutive terminal nucleotide pairs are G-C pairs.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014782 A3

(51) International Patent Classification[7]: C07H 21/04

(21) International Application Number:
PCT/US2004/018848

(22) International Filing Date: 14 June 2004 (14.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

03013296.3	13 June 2003 (13.06.2003)	EP
60/479,354	18 June 2003 (18.06.2003)	US
04002374.9	3 February 2004 (03.02.2004)	EP

(71) Applicant *(for all designated States except US)*: **ALNYLAM PHARMACEUTICALS** [US/US]; 300 Third Street, Cambridge, MA 02142 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **WOPPMANN, Claudia** [DE/DE]; Lerchenweg 9, 95494 Gesees (DE). **VORNLOCHER, Hans-Peter** [DE/DE]; Lise-Meitner-Platz 4, 95448 Bayreuth (DE). **HADWIGER, Philipp** [AT/DE]; Schlesierstr. 6, 96264 Altenkunstadt (DE). **JOHN, Matthias** [DE/DE]; Kapellenstr. 12, 96103 Hallstadt (DE). **LIMMER, Stefan** [DE/DE]; Am Buttergraben 11, D-95326 Kulmbach (DE).

(74) Agents: **GORDON, Dana, M.** et al.; Patent Group, Foley Hoag LLP, Seaport World Trade Center West,, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
9 September 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DOUBLE-STRANDED RIBONUCLEIC ACID WITH INCREASED EFFECTIVENESS IN AN ORGANISM

(57) Abstract: The present invention relates to a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least end of the dsRNA comprises a nucleotide overhang of 1 to 4 unpaired nucleotides in length; wherein the unpaired nucleotide adjacent to the terminal nucleotide pair comprises a purine base; and wherein the terminal nucleotide pair on both ends of the dsRNA is a G-C pair, or at least two of the last four consecutive terminal nucleotide pairs are G-C pairs.

WO 2005/014782 A3